Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 7, 2016, Pages 653-661

  Vigano M ^a   Invernizzi, F ^a   Grossi, G ^a   Lampertico, P ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; TELBIVUDINE; TENOFOVIR; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; INTERFERON;

ADD ON THERAPY; CHRONIC HEPATITIS B; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VIRUS INHIBITION; VIRUS REPLICATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY;

ANTIVIRAL AGENTS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS;

EID: 84981703919     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13751     Document Type: Review

References (36)

1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–85.
2. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661–2.
3. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2012; 2012: 531–61.
4. Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol 2013; 58: 205–9.
5. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice. J Viral Hepat 2012; 19: 377–86.
6. Seto WK, Lam YF, Fung J, et al. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. J Gastroenterol Hepatol 2014; 29: 1028–34.
7. Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015; 60: 1457–64.
8. Lampertico P. Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue? Gut 2015; 64: 526–8.
9. Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding peginterferon to entecavir for HBeAg-positive chronic hepatitis B: a multicentre randomized trial (ARES study). Hepatology 2015; 61: 1512–22.
10. Kittner JM, Spinzl M, Grambihler A, et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J ClinVirol 2012; 54: 93–5.
11. Ouzan D, Penaranda G, Joly H, et al. Add-on peg-interferon leads to loss ofHBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J ClinVirol 2013; 58: 713–7.
12. Lampertico P, Invernizzi F, Facchetti F, et al. Add-on PEG-IFN improves HBsAg kinetics in patients long-term fully suppressed by nucleos(t)ide analogs. J Hepatol 2012; 56: S207.
13. Wu Z, Sheng J, Li L, et al. Improvement of HBsAg loss by additional PEG IFN in nucleosides analogs treated chronic hepatitis B patients. Hepatology 2012; 56: 404A.
14. Li G. Y. Yu, S. Chen, P. Fan, W. Zhang. Sequential combination therapy with NUC and Peg-IFN in HBeAg-positive CHB patients with prior long-term exposure to NUC. Antimicrob Agents Chemother 2015; 59: 4121–8.
15. Chi H, Xie Q, Zhang NP, et al. Addition of peginterferon alfa-2b during long-term nucleos(t)ide analogue therapy increases HBeAg seroconversion and HBsAg decline: week 48 results from a multicenter randomized controlled trial (PEGON Study). Hepatology 2014; 60: 1106A.
16. Lampertico P, Brunetto MR, Craxì A, et al. Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in HBeAg-negative, genotype D chronic hepatitis B patients fully suppressed on nucleot(s)ide analogues treatment: the HERMES Study. J Hepatol 2015; 62: S279.
17. Bourlière M, Rabiega P, Ganne-Carrie N, et al. HBsAg clearance after addition of 48 weeks of PEG-IFN in HBeAg negative CHB patients on NUC therapy with undetectable HBV DNA for at least one year: final results from ANRS-HB06 PEGAN study: a multicenter randomized controlled phase III trial. J Hepatol 2015; 62: S249.
18. Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 2014; 61: 777–84.
19. Han M, Jiang J, Hou J, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study. Antivir Ther 2016; 21: 337–44.
20. Hu P, Shang J, Zhang W, et al. Predictive value of baseline and on-treatment qHBsAg level in HBeAg positive CHB patients who switched from NUCs to pegylated interferon a-2a: a further analysis from NEW SWITCH study. J Hepatol 2015; 62: S251.
21. Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011; 11: 285–300.
22. Su WW, Hsu CW, Lee CM, et al. Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study. J Hepatol 2014; 60: S47.
23. Xie Q, Zhou H, Bai X, et al. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40kD) and entecavir treatment for HBeAg-positive chronic hepatitis B. Clin Infect Dis 2014; 59: 1714–23.
24. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–95.
25. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123–9.
26. Marcellin P, Wursthorn K, Wedemeyer H, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol 2015; 62: 41–7.
27. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675–84.
28. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206–17.
29. Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen negative chronic hepatitis B. AntivirTher 2009; 14: 1165–74.
30. Rijckborst V, Ter Borg MJ, Cakaloglu Y, et al. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol 2010; 105: 1762–9.
31. Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and Peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 2016; 150: 134–44.
32. Chan HL, Ahn SH, Chuang WL, et al. Predictors of clinical response: results from a large, randomized controlled study with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2A (PEG) combination from chronic hepatitis B (CHB). J Hepatol 2015; 62: S251–2.
33. Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2015; 42: 243–57.
34. Liu F, Wang XW, Chen L, et al. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Aliment Pharmacol Ther 2016; 43: 1253–61.
35. Lampertico P, Chan HL, Janssen HL, et al. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther 2016; 44: 16–34.
36. Lin CL, Kao JH. Review article: novel therapies for hepatitis B virus cure - advances and perspectives. Aliment Pharmacol Ther 2016; 44: 213–22.